Characterization of Exosomes Platelets-released

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06298682

Acronym

EXOPLT

Enrollment

175

Registered

2024-03-07

Start date

2021-07-08

Completion date

2027-07-07

Last updated

2024-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Platelet Thrombus

Keywords

exosomes, platelet activation, platelet inhibitors

Brief summary

Extracellular vesicles (EVs) play a key role in cell-to-cell communication. They are small vesicles that contain rich molecular cargo. Recently, they have been proposed as biomarkers for clinical diagnostics. EVs include three classes: small EVs (exosomes), large EVs (microparticles), and apoptotic bodies. Platelet-derived EVs (PEVs) are the most abundant class in human blood and can actively participate in numerous physiological and pathological processes. The information about the role of platelet exosomes in cardiovascular disease and the effect of antiplatelet agents on their release and content is very limited.

Detailed description

This study is a multicentre, observational. We plan to enrol 54 subjects from Centro Cardiologico Monzino IRCCS, and 121 buffy coat related to 121 subjects from Centro Trasfusionale Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. biographical and anthropomorphic data will be recorded, a fasting blood venous sample (from ante-cubital vein) will be collected for the haematochemical analyses and for research samples.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

* subjects without known pathologies

Exclusion criteria

* individuals with gastrointestinal diseases, * individuals with history of hepatic diseases, * individuals with history of urogenital diseases, * individuals with history of hematological diseases, * individuals with history of immunological diseases, * individuals with history of renal diseases, * individuals with history of metabolic diseases * individuals with history of respiratory diseases * individuals with history of cancer * individuals with history of cardiovascular disease * individuals having permanent organ damage * individuals with major trauma in the last 6 months prior to enrollment * individuals with surgery in the last 6 months prior to enrollment * individuals taking medication in the 15 days prior to enrolment.

Design outcomes

Primary

Measure	Time frame
Characterization of exosomes released by activated platelet and exposed to platelet inhibitors by NTA and proteoma analysis	36 month
Characterization of exosomes released by activated platelet by Nanoparticle Tracking Analysis (NTA) and proteoma analysis	36 month

Secondary

Measure	Time frame
Platelet exosome profile emerged by NTA and proteoma analysis will be related with the biographical and anthropometric data of the subjects.	40 month

Countries

Italy

Contacts

Primary ContactSilvia S Barbieri, PhD

silvia.barbieri@ccfm.it0258002021

Outcome results